Targeting macrophages in liver fibrosis
Clinical Scorecard: Modulating Macrophage Activity in Hepatic Fibrosis
At a Glance
| Category | Detail |
|---|
| Condition | Hepatic Fibrosis |
| Key Mechanisms | Macrophages modulate inflammatory signals, immune regulation, and tissue repair. |
| Target Population | Patients with chronic liver diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD). |
| Care Setting | Clinical settings focused on liver disease management. |
Key Highlights
- Fibrosis is a dynamic process involving excessive ECM deposition.
- Macrophages play a central role in both fibrogenesis and fibrosis resolution.
- Hepatic macrophages exhibit diverse activation states beyond the classical M1/M2 paradigm.
- Liver fibrosis is potentially reversible, linked to macrophage reprogramming.
- Current therapeutic strategies are shifting towards promoting pro-resolution programs.
Guideline-Based Recommendations
Diagnosis
- Assess liver fibrosis through imaging and biopsy when necessary.
Management
- Consider macrophage-targeted therapies to promote fibrosis resolution.
Monitoring & Follow-up
- Regularly evaluate liver function and fibrosis progression.
Risks
- Chronic liver disease can lead to organ dysfunction and increased mortality.
Patient & Prescribing Data
Individuals with chronic liver diseases, particularly those with MASLD.
Therapies should focus on macrophage reprogramming and enhancing efferocytosis.
Clinical Best Practices
- Utilize targeted therapies that promote macrophage pro-resolution programs.
- Monitor changes in macrophage activity as part of treatment evaluation.
Related Resources & Content
